Short answer
ATM is a DNA-repair gene included on many hereditary breast, pancreatic, prostate, and broad cancer panels. A germline pathogenic or likely pathogenic ATM result can change breast cancer screening discussions and may raise pancreatic, prostate, and other risk questions depending on the exact variant and family history. A person with one ATM pathogenic variant is not expected to have ataxia-telangiectasia, but relatives and reproductive partners may need different counseling when family testing reveals ATM variants on both sides. An ATM VUS is uncertain and should not be treated like a confirmed harmful variant.
How to read the result
| Report wording | Practical meaning | What to ask next |
|---|---|---|
| Pathogenic or likely pathogenic ATM variant | The lab found an ATM change with enough evidence to be handled as harmful for inherited-risk counseling. | Which breast, pancreatic, prostate, or family-testing steps are supported for this exact variant and family history? |
| ATM variant of uncertain significance | The lab found an ATM change, but the cancer-risk meaning is not established. | How should care be based on personal and family history while the variant remains uncertain? |
| Negative ATM result | No reportable ATM variant was found in the test performed. | Was there a known family variant, and were other hereditary cancer genes included? |
| Tumor-only ATM finding | The result may reflect a change in cancer tissue rather than inherited DNA. | Is separate germline testing needed before relatives are told to test? |
| Two ATM pathogenic variants | Biallelic ATM variants can cause ataxia-telangiectasia or related presentations, which is a different counseling question than a single inherited cancer-risk variant. | Is this about cancer risk only, or is ataxia-telangiectasia evaluation and reproductive counseling also needed? |
Cancer-risk questions to clarify
- Breast cancer risk is the main ATM hereditary cancer discussion, but the plan depends on the exact variant, age, sex, personal history, and family history.
- Some ATM variants may carry higher breast cancer risk than others, so exact variant notation matters more than the gene name alone.
- Pancreatic and prostate cancer risk may be relevant, especially when those cancers appear in the family, but screening decisions should be individualized with genetics-aware care.
- Other cancer associations are less settled; do not turn broad ATM headlines into a personal screening plan without current clinical guidance.
- Radiation sensitivity questions should be discussed in context. A single ATM pathogenic variant is not the same as having ataxia-telangiectasia.
When family history changes the interpretation
Follow-up matters more when the ATM result came from tumor testing, when breast, pancreatic, or prostate screening depends on exact variant class, or when family history is stronger than the report alone. Genetics counseling can help separate inherited risk from a tumor-only clue and decide whether relatives need targeted testing.
Questions to bring to counseling
- Is this a germline result from blood, saliva, cheek cells, or another normal sample, or was ATM found only in tumor testing?
- What is the exact ATM variant notation and classification?
- Is this a higher-risk ATM variant or a more typical moderate-risk variant?
- Which parts of my breast, pancreatic, prostate, or other screening plan come from ATM, and which come from family history alone?
- Do relatives need targeted testing for a known family variant?
- Could reproductive counseling matter if both biological parents carry pathogenic ATM variants?
- How will I be notified if an ATM VUS is reclassified?
Related guides: CHEK2 genetic testing result interpretation, PALB2 genetic testing result interpretation, BRCA VUS result interpretation, BRCA testing vs broad cancer panels, and tumor genomic vs inherited genetic testing.
When follow-up matters more
Follow-up matters more when the ATM result came from tumor testing, when there is a strong family history that the test does not fully explain, or when the possibility of biallelic ATM variants changes reproductive counseling for the family. In those cases, paired tumor-normal testing or genetics review can clarify whether relatives should be tested and how the result should be used.
FAQ
What does a pathogenic ATM result usually mean?
A pathogenic or likely pathogenic ATM result can support hereditary cancer counseling and may affect breast, pancreatic, prostate, and family-testing discussions depending on the exact variant and family history.
Is an ATM VUS actionable?
No. An ATM variant of uncertain significance should not be treated like a confirmed harmful variant.
Does a negative ATM result rule out inherited risk?
Not necessarily. A negative result can be uninformative if there is a known family variant or if other hereditary cancer genes were not tested.
Does a tumor-only ATM finding prove inheritance?
No. A tumor-only ATM change may reflect cancer tissue rather than inherited DNA and may need germline confirmation before relatives are told to test.
Do relatives need targeted testing?
When a confirmed familial pathogenic ATM variant is known, relatives may be offered targeted testing for that exact variant.
Why does biallelic ATM matter?
Two pathogenic ATM variants can point to ataxia-telangiectasia or related counseling, which is a different question than a single inherited cancer-risk variant.
Can paired tumor-normal testing help with ATM?
Yes. Paired testing can help show whether an ATM change is confined to the tumor or also present in normal DNA, which changes how family-risk counseling is handled.